Quantum Genomics has joined the Pass French Tech p
Post# of 301275
PARIS and NEW YORK, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC) , a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today presented its financial calendar for 2017:
- March 30, 2017 – 2016 annual financial results (after market close)
- June 8, 2017 – General shareholders meeting
- October 3, 2017 – 2017 half-year financial results (after market close)
In 2017, Quantum Genomics will also take part in major international conferences:
- March 14-15, 2017 – Bio Asia (Tokyo, Japan)
- June 16-19, 2017 – European Meeting on Hypertension and Cardiovascular Protection organized by the ESH - European Society of Hypertension - (Milan, Italy)
- June 19-22, 2017 – Bio International Convention (San Diego, United States)
- Aug. 30-Sept. 2, 2017 – Symposium ISAN 2017 (Nagoya, Japan)
- October 11-13, 2017 – Bio Japan (Nagoya, Japan)
Quantum Genomics joins the Pass French Tech selection of 2016-2017
Quantum Genomics is pleased to announce that it recently joined the national Pass French Tech program of the 2016-2017 selection, intended for hyper-growth companies. The primary mission of this program is to provide services to these companies that specifically respond to the issues associated with hyper-growth, including providing access to funding and furthering their international development.
To achieve this, the program relies on the services of French organisations such as Bpifrance (innovation bank), the Direction Générale des Entreprises (corporations management committee), Business France (international development), the Compagnie Française d'Assurance pour le Commerce Extérieur (export insurance), the Institut National de la Propriété Industrielle (patents institute), the Association Française des Pôles de Compétitivité (competitiveness clusters association) and the Association Française des Investisseurs pour la Croissance (association of investors for growth).
For more information, visit www.lafrenchtech.com
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.
The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com .
Twitter: @ALQGC_EN LinkedIn: Quantum Genomics
CONTACTS Quantum Genomics Lionel Ségard Chairman & Chief Executive Officer +33 1 85 34 77 77 Quantum Genomics Marc Karako CFO – Investor Relations +33 1 85 34 77 75 marc.karako@quantum-genomics.com ACTUS finance & communication (Europe) Jean-Michel Marmillon Press Relations +33 1 53 67 36 73 / jmmarmillon@actus.fr The Ruth Group (U.S.) Lee Roth / Kirsten Thomas Investor / Public Relations +1 646-536-7012 / +1 508-280-6592
(0)
(0)